Thyroid Nodule Diagnostic Markers in the Face of the New Diagnosis, NIFT-P: Time for a Reset?

Related Articles

Thyroid Nodule Diagnostic Markers in the Face of the New Diagnosis, NIFT-P: Time for a Reset?

Thyroid. 2017 Aug 31;:

Authors: Sahli ZT, Umbricht CB, Schneider EB, Zeiger MA

Abstract
Current thyroid molecular tests are specifically designed for the differential diagnosis of nodules with indeterminate or suspicious fine needle aspiration (FNA) cytology. However, their clinical validity faces challenges from both variation among institutions in cancer prevalence and, most recently, the new category of non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFT-P). The latter diagnosis was previously classified as malignant. Relevant to this, all molecular panels on the market today were originally tested and validated within the context of these entities being considered malignant. Herein, we examine possible effects of NIFT-P reclassification as a benign entity on the original validation studies and, investigate the effect of the significant reported variability in thyroid cancer prevalence on the performance of these tests.

PMID: 28859553 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2wvXDe4